doi:10.1182/blood-2003-06-1850Prepublished online December 30, 2003;
Dominique Rigal, Krzystof Warzocha, Bertrand Coiffier and Gilles SallesEwa Lech-Maranda, Lucile Baseggio, Jacques Bienvenu, Carole Charlot, Francoise Berger, outcome of diffuse large B-cell lymphomaThe interleukin-10 gene promoter polymorphisms influence the clinical
(4217 articles)Neoplasia � (4939 articles)Immunobiology �
(3667 articles)Clinical Trials and Observations �Articles on similar topics can be found in the following Blood collections
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requestsInformation about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprintsInformation about ordering reprints may be found online at:
http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtmlInformation about subscriptions and ASH membership may be found online at:
articles must include the digital object identifier (DOIs) and date of initial publication. priority; they are indexed by PubMed from initial publication. Citations to Advance online prior to final publication). Advance online articles are citable and establish publicationyet appeared in the paper journal (edited, typeset versions may be posted when available Advance online articles have been peer reviewed and accepted for publication but have not
Copyright 2011 by The American Society of Hematology; all rights reserved.Washington DC 20036.by the American Society of Hematology, 2021 L St, NW, Suite 900, Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
1
The interleukin-10 gene promoter polymorphisms
influence the clinical outcome of diffuse large B-cell lymphoma
Short title: IL-10 polymorphisms and lymphoma outcome
Ewa Lech-Maranda1,2, Lucile Baseggio 1,3, Jacques Bienvenu 1,4, Carole Charlot 1,3, Françoise
Berger 1, 5 Dominique Rigal 1, 6, Krzysztof Warzocha7, Bertrand Coiffier1,3 and Gilles Salles1,3
1Equipe d’Accueil 3738 «Pathologie des Cellules Lymphoïdes », Université Claude Bernard, Lyon,
France; 2Department of Hematology, Medical University of Lodz, Poland; 3Service d’Hématologie, 4Laboratoire d’Immunologie, 5Service d’Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Pierre-
Bénite, France; 6 Etablissement Français du Sang, Lyon, France; 7Institute of Hematology and Blood
Transfusion, Warsaw, Poland
E. Lech-Maranda was supported by the UICC International Cancer Technology Transfer. This work
was supported by the Comité du Rhône de la Ligue contre le Cancer and les Hospices Civils de Lyon
(PHRC 2002).
Corresponding author:
Gilles Salles, MD. Ph. D.
Service d’Hématologie, Centre-Hospitalier Lyon-Sud, 69495 Pierre-Bénite, France
Tel: 33 (0)4 78 86 11 91; fax: 33 (0)4 78 86 65 66
e-mail: [email protected]
Word counts : Abstract 187 ; Text 2805
Scientific category : Neoplasma
Blood First Edition Paper, prepublished online December 30, 2003; DOI 10.1182/blood-2003-06-1850
Copyright (c) 2003 American Society of Hematology
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
2
ABSTRACT
The aim of the study was to investigate whether interleukin-10 (IL-10) genetic
polymorphisms influence this cytokine production as well as the incidence and outcome of
diffuse large B-cell lymphoma (DLBCL). The frequency of IL-10-1082G allele was found to be
higher in 199 DLBCL patients as compared to 112 controls (0.47 versus 0.39, P=.043).
Increased serum levels of IL-10 was associated with adverse prognostic factors and poor
DLBCL outcome. The frequencies of IL-10-819T and IL-10-592A alleles were lower in patients
with elevated IL-10 serum levels (0.155 versus 0.32, P=0.14). As compared to patients
carrying the IL-10-1082AA genotype, those with the IL-10-1082G allele (IL-10-1082GG/GA
genotypes) had higher complete remission rate (78% [CI 71%-85%] versus 65% [CI 52%-
78%], P=.07), 5-years freedom from progression (FFP) (60% [CI 52%-68%] versus 40% [CI
27%-53%], P=.013) and overall survival (OS) (63% [CI 55%-71%] versus 33% [CI 20%-
45%], P=.0009). Among factors of the International Prognostic Index, IL-10-1082G allele
remained an independent variable predicting longer FFP (RR [relative risk]=.76, P=.00035)
and OS (RR=.78, P=.0015). These results indicate that IL-10 production contributes to the
clinical course of DLBCL and that this phenomenon involves a substantial genetic
component.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
3
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin's
lymphoma (NHL) entity in the North America and Western Europe. The disease incidence is
increasing but etiological factors contributing to this phenomenon remain still largely
unknown.1 Although it is a curable disease, many patients do not achieve complete remission
(CR) or they relapse after conventional chemotherapy. The formulation of the International
Prognostic Index (IPI) has provided generally accepted criteria to identify specific risk groups
of DLBCL and to design appropriate therapies. The clinical prognostic features incorporated
in the IPI, including age, lactate dehydrogenase (LDH) level, performance status, clinical
stage and number of extranodal sites, mostly reflect the disease’s extension and the patient’s
characteristics.2,3 These tumour- and host-related parameters are likely to reflect some
underlying biological mechanisms. It has been suggested that immune system alterations may
be linked to the incidence and clinical course of lymphomas.4 Therefore, attempts to clarify
the mechanisms involved in immune system deregulation in lymphoma should contribute to a
better understanding of the clinical course of this malignancy.
Interleukin-10 (IL-10) is an important immuno-regulatory cytokine mainly produced
by monocytes and macrophages, T cells as well as normal and neoplastic B lymphocytes. IL-
10 plays a key role in controlling the balance between cellular and humoral immune
responses. IL-10 has strong immunosuppressive effects via the inhibition of pro-inflammatory
T helper 1 (Th1) lymphocytes, and conversely stimulates the proliferation and differentiation
of B and Th2 cells.5 Numerous studies have shown that IL-10 may be involved in the
pathogenesis of lymphoid disorders.5-8 It has been found to act as an autocrine growth factor
which up-regulates bcl-2 expression in some B-cell malignancies.7,8 Increased serum IL-10
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
4
levels were also found to be associated with poor prognosis and shorter survival of the
patients with NHL and Hodgkin’s lymphoma.9-11
The precise mechanisms engaged in the regulation of IL-10 production remain
undetermined, although inherited factors appear to play an important.12 The gene encoding
IL-10 is located on chromosome 1 (1q31-1q32).13,14 It has been reported that three single
nucleotide polymorphisms in the IL-10 gene promoter, including IL-10-1082, IL-10-819 and IL-
10-592, may influence IL-10 production in vitro.15 In addition, associations of these
polymorphisms with the incidence or clinical outcome of various infectious or inflammatory
disorders indicate that genetic variations within the IL-10 locus might be also functionally
relevant in vivo. 12, 16-20
In the present study we report that DLBCL patients have a higher frequency of
the IL-10-1082G allele than ethnically-matched healthy individuals in the French population.
Increased serum levels of IL-10 was associated with numerous adverse prognostic factors and
poor DLBCL outcome. Importantly, the frequencies of the IL-10-819T and IL-10-592A alleles
were lower in patients with elevated IL-10 serum levels and IL-10-1082G allele was associated
with longer freedom from progression (FFP) and overall survival (OS). These results indicate
that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon
involves substantial genetic component.
MATERIALS AND METHODS
Subjects
The study comprised of 199 consecutive patients with DLBCL treated at the
Department of Hematology of the Centre Hospitalier Lyon-Sud and 112 unrelated ethnically-
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
5
matched healthy blood donors (Etablissement Français du Sang, Lyon, France). All samples
for genetic analysis were obtained after informed consent and coded. The patients’
confidentiality was preserved in accordance with the guidelines for studies of human subjects
in our institution.
The initial medical evaluation consisted of a complete history and physical
examination, computed tomographic scan of the chest, abdomen and pelvis, blood
morphology and chemistry. The extent of the disease was categorized according to the Ann
Arbor classification, and performance status was assessed using Eastern Cooperative
Oncology Group (ECOG) criteria. Clinical characteristics of the patients enrolled in the study
are shown in Table 1.
Treatment
All patients included in this study received anthracyclin-containing regimens,
consisting of CHOP (cyclophosphamide, adriamycine, vincristine, prednisone) or high-dose
CHOP 21 according to the age and number of IPI factors. No patients received rituximab as a
part of the first line regimen. Complete remission (CR) was defined as the disappearance of
all disease manifestations and normalization of all laboratory values. Freedom from
Progression (FFP) survival was determined from the onset of treatment until relapse, disease
progression, or the last follow-up evaluation. Overall survival (OS) was determined from the
onset of treatment until the last follow-up evaluation or death from any cause.
Among 199 patients, 148 (74%) achieved CR, whereas 51 (26%) did not. Eighty-two
patients (41%) have experienced disease progression, and 77 (39%) patients died. The median
follow-up for the patients remaining alive was 42 months (range: 9-196 months).
Genotyping analyses
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
6
Genomic DNA from peripheral blood mononuclear cells was extracted using High
Pure PCR Template Preparation Kit (Roche, Mannheim, Germany). IL-10-1082 polymorphism
was genotyped using an allele-specific polymerase chain reaction (ASPCR). The specific
primers pair S (5’-CCCCAGGTAGAGCAACACTCC) with B1 (5’-
CCTATCCCTACTTCCCCC) or B2 (5’-CCTATCCCTACTTCCCCT) were used to amplify
a 153-bp fragment of the IL-10 gene, which includes the polymorphic site at the nucleotide
position -1082.22 Each sample was tested with both primers pairs, i.e. S-B1 and S-B2. The
primers pair S with AS (5’-ACACCATCTCCAGCACATAG) was used to amplify the IL-10
gene’s fragment of 325 bp which served as an internal control and a genomic DNA template
for sequencing. Primer AS was also used as a competitor for the primer pairs S-B1 and S-B2
to improve the specificity of the ASPCR assay.23 After heating at 950 C for 10 minutes, PCR
amplification was performed with 30 cycles: 950 C for 30 seconds; 600 C for 60 seconds; 720
C for 60 seconds; followed by a final extension step at 720 C for 7 minutes. PCR products
were stained and visualized on a 2% agarose gel with ethidium bromide.
All IL-10-1082 genotyping results were independently confirmed using another allelic
discrimination assay with specific fluorescent dye-labeled (FAM and VIC) MGB probes
(Applied Biosystem, Foster City, CA, USA) and real time PCR analysis performed on an ABI
PRISM 7700 Sequence Detector (Applied Biosystem). The forward (5’-CAAATCCAAGAC
AACACTACTAAGGC) and reverse (5’-GGGTGGAAGAAGTTGAAATAACAAG)
primers’ pair, and MGB probes specific for the IL-10-1082G (CTTCCCCCTCCCAAA) and IL-
10-1082A (CTTCCCCTTCCCAAAG) alleles were used to amplify the 135 bp fragment of the
IL-10 promoter. PCR conditions were used as following: 500 for 2 minutes, 950 C for 10
minutes, and after 40 cycles with 920 C for 15 seconds and 620 C for 60 seconds.
IL-10-819 and IL-10-592 polymorphisms were genotyped using a PCR-based restriction
fragment length polymorphism (PCR-RFLP).24 PCR-amplified products of 588bp were
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
7
obtained with the use of upstream (5’-ATCCAAGACAACACTACTAA) and downstream
(5’-TAAATATCCTCAAAGTTCC) primers. PCR amplification was performed with 30
cycles: 950 C for 30 seconds; 540 C for 60 seconds; 720 C for 60 seconds; followed by a final
extension step at 720 C for 7 minutes. The PCR-amplified products were digested overnight
with 0.75 U of MaeIII (Roche Diagnostic GmbH, Mannheim, Germany) for the IL-10-819
polymorphism or with 8 U of RsaI (Promega Corporation, Madison, WI, USA) for the
IL-10-592 polymorphism. Digested PCR products were separated by electrophoresis on a 10%
polyacrylamide gel.
To confirm the accuracy of the ASPCR and PCR-RFLP assays, amplification products
from 2 individuals homozygous and 1 heterozygous for each polymorphic allele were purified
from the gel, ligated into pGEM-T vector (Promega) and subcloned. Recombinant plasmid
DNAs were sequenced using Alf ExpressTM DNA Sequencer (Pharmacia Biotech, Uppsala,
Sweden). In every studied case, the results of IL-10-1082, IL-10-819, IL-10-592 genotyping
obtained by sequencing were the same as using ASPCR or RFLP methods.
Evaluation of serum IL-10 levels
Blood samples from 149 newly diagnosed patients were collected before treatment
initiation using sterile tubes containing EDTA to prevent further release of cytokine from
circulating mononuclear cells. Serum samples were stored at -800 C and thawed immediately
before the determination of IL-10 level using an human enzyme-linked immunoabsorbent
assay (ELISA) (BioSource International, Inc., California, USA). The detection limit of the test
was 5 pg/mL.
Patients with active bacterial or fungal infection, and those who tested positive for the
human immunodeficiency virus as well as patients with a previous history of autoimmune
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
8
disease and those who had received recent corticosteroid therapy were excluded from the
analysis.
Statistical analysis
Associations between allele frequencies or genotype distributions and clinical or
biological variable were assessed with the χ2 test with Yates’s correction when a cell
frequency was less than 20 unless any expected frequency was less than 5, when Fisher’s
exact test was used. Survival (FFP and OS) were estimated by the Kaplan-Meier method and
compared using the log-rank test. A multivariate regression analysis with the Cox
proportional hazard model was used to adjust the effect of the IL-10 polymorphisms along
with variables of the IPI for potential independent prognostic factors. Only patients with
complete data were entered into the regression procedure (n=175). Statistical tests with P<.05
were considered significant. Statistical analysis was performed using the Statistica package
(StatSoft, Tulsa, OK). Confidence interval (95%) were calculated.
RESULTS
IL-10-1082, -819, - 592 polymorphisms in DLBCL patients and healthy controls
The frequency of IL-10-1082G allele was higher in lymphoma patients as compared to
healthy controls (0.47 versus 0.39, P=.043) which translated into a higher frequency of IL-10-
1082GG/GA genotypes in the former population (72%, [CI 66%-78%] versus 60%, [CI 51%-
69%], P=.023). Allelic frequencies and distributions at the IL-10-819 and IL-10-592
polymorphisms did not differ between both studied populations (Table 2).
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
9
IL-10-1082, -819, - 592 polymorphisms and IL-10 serum levels in patients with DLBCL
Only 149 DLBCL patients had available samples for IL-10 ELISA assays at diagnosis.
Of those, 117 patients (79%) had IL-10 serum levels below the detection limit (<5 pg/mL)
and 32 (21%) above this value (median=31.5 pg/mL, range: 5 to 2480 pg/mL). Detectable IL-
10 serum levels were associated with age>60 years, ECOG status ≥ 2, disease stage III/IV,
elevated serum LDH and β2-microglobulin levels, presence of B symptoms, anemia and low
serum albumin levels as well as with intermediate-high and high risk groups according to the
IPI (Table 1). As compared to the patients with IL-10 serum levels below the detection limit,
patients with elevated cytokine levels had significantly lower CR rate (50% [CI 33%-67%,]
versus 82% [CI 75%-89%], P=.0005), lower estimated 5-years FFP (24% [CI 10%-39%]
versus 66% [CI 57%-74%], P=.0015) and lower 5-years OS (32% [CI 16%-48%] versus 65%
[CI 56%-74%], P=.0009).
With respect to IL-10 gene polymorphisms, the frequencies of IL-10-819T and IL-10-
592A alleles were lower in the patients with elevated IL-10 serum levels versus below its
detection limit (0.155 versus 0.32, P=0.14). This translated into a higher frequency of IL-10-
819CC/IL-10-592CC genotypes in the former group (72% [CI 56%-87%] versus 45% [CI 36%-
54%], P=.014). No associations were found between IL-10 serum levels and allelic or
genotype variations within IL-10-1082 polymorphism (Table 3).
The fifty patients for which samples for IL-10 serum level evaluation were not
available did not differ from the remaining 149 patients in terms of genotyping, laboratory or
clinical profiles nor FFP and OS intervals (not shown).
IL-10-1082, -819, - 592 polymorphisms and DLBCL outcome
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
10
Among 199 patients with DLBCL, no associations were found between IL-10-1082G
allele and prognostic variables listed in Table 1 except of male gender (P=.026) and age <60
years (P=.032).
As compared to the patients carrying the IL-10-1082AA genotype, those with IL-10-1082G
allele (IL-10-1082GG/GA genotypes) had slightly higher complete remission rate (78% [CI 71%-
85%] versus 65% [CI 52%-78%], P=.07), and presented higher estimated 5-years FFP (60%
[CI 52%-68%] versus 40% [CI 27%-53%], P=.013) and higher 5-years OS (63% [CI 55%-
71%] versus 33% [CI 20%-45%], P=.0009) (Fig. 1). No associations were found between the
prognostic variables, FFP or OS intervals and IL-10-1082GG genotype or allele/genotype
distributions within the IL-10-819, -592 polymorphisms.
After incorporating IL-10-1082G allele and all prognostic variables of the IPI in a
multivariate Cox regression model, the IL-10-1082G allele was found to be an independent
variable predicting longer FFP survival (RR [relative risk]=.76, P=.00035), followed by LDH
serum levels within normal values (RR=.76, P=.0027), disease stage I/II (RR=.81, P=.043)
and number of extranodal sites <2 (RR=.83, P=.048) (total R2=.85, P<.0001). Using the same
variables, IL-10-1082G allele (RR=.78, P=.0015) followed by LDH serum levels within normal
values (RR=.78, P=.0076), disease stage I/II (RR=.78, P=.021), and number of extranodal
sites <2 (RR=.81, P=.033) were retained in the multivariate predictive model for longer OS
(total R2= .85, P<.0001).
DISCUSSION
IL-10 is a pleiotropic immunomodulatory cytokine which plays a crucial role in
normal ontogenesis and function of the immune system. It is also involved in the acute and
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
11
chronic inflammatory responses that accompany various infectious, autoimmune and
lymphoproliferative disorders.5 The results of the present study confirms previous
observations9-11,25,26 that elevated IL-10 serum levels are associated with adverse prognostic
factors and predict poor DLBCL outcome, and for the first time links this observation to IL-
10 genetic polymorphisms.
We observed that IL-10 serum levels mainly reflect tumor burden (advanced disease
stage, elevated LDH and β2-microglobulin serum levels) and host-tumor relationship
(presence of B symptoms, anemia, low serum albumin levels). These data suggest that IL-10
might be produced by both lymphoma as well as bystander reactive cells.27,28 It seems likely
therefore that increased serum levels of IL-10 reflects an enhanced activation of the immune
system upon more aggressive disease but its potential action as a growth factor for lymphoma
cells or as a suppressor of macrophages or T-cell functions should also be taken into
account.29
In vitro studies revealed that IL-10 production could be related to its gene promoter
polymorphisms.15 Several studies such as those assessing the susceptibility to Epstein-Barr
virus infection, the severity of autoimmune diseases or graft versus host disease (GVHD),
were performed in different ethnic groups and indicated that distinct IL-10 alleles or
haplotypes were a key factor of IL-10 production in vivo.16,17,22,30 These observations raise the
possibility that susceptibility and clinical course of disorders in which immune activation
plays an important pathogenic role could be related to the genetic control of IL-10 production.
In the present study, an moderate excess of the IL-10-1082G allele was found among the
patients with DLBCL as compared to ethnically-matched healthy controls. The allelic
frequencies and distributions of the IL-10-819 and IL-10-592 polymorphisms did not differ
between both cohorts. These data suggest that the presence of the IL-10-1082G allele (or
eventually another allelic variation genetically linked to the former) may contribute to the
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
12
genetic background of DLBCL occurrence. On the other hand, since the observed difference
in the prevalence of IL-10-1082G allele between patients and controls was only marginally
significant, it is not possible to exclude the presence of a bias towards an over-representation
of this particular subgroup of individuals in the present cohort of patients with DLBCL. Other
similar studies are therefore warranted.
The frequencies and distributions of the IL-10-1082, -819, -592 polymorphic alleles in the
present population of healthy controls were similar to those observed in bone marrow donors
from the French population independently obtained by Socié et al.31 These allelic frequencies
were different as compared to the healthy individuals from Manchester and South-East
England and particularly from Southern China.15,32-34 It seems likely therefore that highly
polymorphic IL-10 promoter variations reflects different prevalent haplotypes in various
ethnic groups.
In the present study, we observed the association between the presence of the IL-10-
819T or IL-10-592A alleles and low IL-10 serum levels at the time of initial DLBCL
presentation. This remains in line with observations of others indicating lower capability of
IL-10 production for the IL-10-819T or IL-10-592A alleles and higher for the IL-10-1082GG
genotype.15-20 Although we did not find an association between IL-10-1082GG genotype and
increased IL-10 serum levels, this could be limited by the low patients number in this
particular subgroup (n=8). Overall, these data suggest that genetic control of IL-10 production
influences the serum levels of this cytokine in DLBCL patients.
The most striking evidence for the clinical significance of IL-10 promoter gene
polymorphisms in DLBCL was the observed association of the IL-10-1082G allele and a
favorable disease outcome. Since no associations were found between the FFP or OS intervals
and allelic variations within IL-10-819,-592 polymorphisms, these results indicate that DLBCL
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
13
outcome was solely related to the IL-10-1082G and could not be explained by the remaining
alleles.
Because IL-10-1082G was previously found to be associated with high IL-10-producing
capability15-20, our data suggest that increased IL-10 production within tumor
microenvironment might be of protective value and conversely, that low IL-10-producing
capability makes individuals susceptible to more aggressive course of the disease. For
example, IL-10 was found to increase T-cell cytotoxicity, to inhibit tumor angiogenesis and to
antagonize the action of proinflammatory cytokines.35-37 Alternatively, the influence of
clinical course of DLBCL by the IL-10-1082G may imply others genes residing close to this
locus. Other studies regarding the role of tumor necrosis factor and HLA class II
polymorphisms in patients with lymphoma have also indicated that a single allele could not
account for the variability of the disease outcome.38,39 Similar observations were obtained in
GVHD and other clinical conditions.20, 22
In summary, our findings demonstrate that IL-10 production contributes to the clinical
course of DLBCL and that this phenomenon involves a substantial genetic component.
Further identification of inherited genetic markers associated with clinical aggressiveness of
lymphoma can guide the search for immunological mechanisms underlying that variability.40
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
14
REFERENCES
1. Groves FD, Linet MS, Travis LB, et al. Non-Hodgkin's lymphoma incidence by histologic
subtype in the United States From 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-
1251.
2. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-
Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
3. Swan F, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell
lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J Clin
Oncol. 1989;7:1518-1527.
4. Caligaris-Cappio F. How immunology is reshaping clinical disciplines: the example of
haematology. Lancet. 2001;358: 49-55.
5. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10
receptor. Ann Rev Immunol. 2001;19:683-765.
6. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived
from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma
constitutively secrete large quantities of interleukin-10. Blood. 1992;80:1289-1298.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
15
7. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and
differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA.
1992;89:1890-1893.
8. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells
by induction of the bcl-2 protein. J Clin Invest. 1994;93:424-428.
9. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in
serum of adults with Hodgkin’s disease and are associated with inferior failure-free
survival. Ann Oncol. 1999;10:433-440.
10. Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin’s lymphoma: a
prognostic factor. Blood. 1993;82:2169-2174.
11. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic
lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood.
2001;97:256-2563.
12. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine
production in meningococcal disease. Lancet. 1997;349:170-173.
13. Kim JM, Brannan CI, Copeland NG, et al. Structure of the mouse IL-10 gene and
chromosomal localization of the mouse and human genes. J Immunol. 1992;148:3618-
3623.
14. Eskdale J, Kube D, Tesch H, et al. Mapping of the human IL10 gene and further
characterization of the 5' flanking sequence. Immunogenetics. 1997;46:120-128.
15. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the
interleukin-10 gene promoter. Eur J Immunogenetics. 1997;24:1-8.
16. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between
polymorphism at the human IL-10 locus and systemic lupus erythematosus. Tissue
Antigens. 1997;49:635-639.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
16
17. Lim S, Crawley E, Woo P, Barnes P: Haplotype associated with low interleukin-10
production in patients with severe asthma. Lancet. 1998;352:113.
18. Hulkkonen J, Pertovaara M, Antonen J, et al. Genetic association between interleukin-10
promoter region polymorphisms and primary Sjogren's syndrome. Arthritis Rheum. 2001,
44:176-179.
19. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes
of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and
are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis
Rheum. 1999;42:1101-1108.
20. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha
and IL-10) polymorphisms in inflammatory bowel diseases and normal controls:
differential effects on production and allele frequencies. Genes Immun. 2000;1:185-190.
21. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a
multicenter study of intensive chemotherapy in 737 patients with aggressive malignant
lymphoma. J Clin Oncol. 1989;7:1018-1026.
22. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and
interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-
host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:
3941-3946.
23. Zhu KY, Clark JM. Addition of a competitive primer can dramatically improve the
specificity of PCR amplification of specific alleles. Biotechniques. 1996;21:586-590.
24. Coakley G, Mok CC, Hajeer AH, et al. Interelukin-10 promoter polymorhisms in
rheumatoid arthrits and Felty’s syndrome. B J Rheumatol. 1998;37:988-991.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
17
25. Bohlen H, Kessler M, Sextro M, et al. Poor clinical outcome of patients with Hodgkin's
disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10
serum levels for Hodgkin's disease. Ann Hematol. 2000;79:110-113.
26. Viviani S, Notti P, Bonfante V, et al. Elevated pretreatment serum levels of Il-10 are
associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute
experience. Med Oncol. 2000;17:59-63.
27. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell IL-10: B cell lines derived from
patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma
constitutively secrete large quantities of IL-10. Blood. 1992;80:1289-1298.
28. Emilie D, Touitou R, Raphael M, et al. In vivo production of interleukin-10 by malignant
cells in AIDS lymphomas. Eur J Immunol. 1992;22:2937-2942.
29. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in
vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
Cancer Res. 1996;56:5499-5505.
30. Helminen M, Lahdenpohja N, Hurme M. Polymorhism of the interleukin-10 gene is
associated with susceptibility to Epstein-Barr virus infection. J Infect Dis. 1999;180:496-
499.
31. Socié G, Loiseau P, Tamozua R, et al. Both genetic and clinical factors predict the
development of graft-versus-host disease after allogeneic hematopoietic stem cell
transplantation. Transplantation 2001;72:699-706.
32. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping for polymorphisms in interferon-
gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-
alpha genes: a technical report. Transpl Immunol. 1998;6:193-197.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
18
33. Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the
tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in
a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27:241-249.
34. Mok CC, Lanchbury JS, Chan DW, et al. Interleukin-10 promoter polymorphisms in
Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum.
1998;41:1090-1095.
35. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of
Burkitt lymphoma by interleukin-10. Blood. 2000;96:2568-2573.
36. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-
10 on human CD8+ T cells. J Immunol. 1998;60:3188-3193.
37. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the
immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol.
1999;162:1723-1729.
38. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis
factor region and non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
39. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II (HLA
DRB1) and tumor necrosis factor genetic polymorphisms are independent predictors of
non-Hodgkin's lymphoma outcome. Blood. 2002;100:3037-3040.
40. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med.
2002;346:1937-1947.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
19
Table 1. Characteristics of 199 patients with DLBCL and their associations with
IL-10 serum levels in 149 patients who provided samples available for ELISA at
the time of initial presentation.
Characteristics All patients Patients with Patients with IL-10 (< 5 pg/mL) IL-10 (≥ 5 pg/mL) P values*
n=199 n=117 n=32
Sex nsFemale 104 (52 %) 63 (54%) 16 (50%)Male 95 (48 %) 54 (46%) 16 (50%)
Age .01
≤ 60 years 104 (52 %) 65 (56%) 9 (28%)> 60 years 95 (48 %) 52 (44%) 23 (72%)
Performance status (ECOG) .001< 2 137 (69 %) 89 (76%) 16 (50%)≥ 2 54 (27%) 21 (18%) 16 (50%) unknown 8 7
B symptoms .0004 absent 141 (71 %) 94 (80%) 15 (47%) present 58 (29 %) 23 (20%) 17 (53%)
Ann Arbor stage .007I,II 78 (39 %) 51 (43%) 6 (19%)III,IV 110 (55 %) 57 (49%) 26 (81%)unknown 11 9
Serum LDH .005 ≤ 1 x normal 77 (39 %) 56 (48%) 7 (22%)> 1 x normal 106 (53 %) 49 (42%) 24 (75%)
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
20
unknown 16 12 1
Serum β2-microglobulin <.0001 ≤ 3.0 mg/L 125 (63 %) 81 (69%) 12 (37.5%)> 3.0 mg/L 50 (25 %) 20 (17%) 20 (62.5%)unknown 24 16
No of extranodal sites ns < 2 116 (58 %) 71 (61%) 16 (50%)≥ 2 67 (34 %) 35 (30%) 13 (41%)unknown 16 11 3
Serum albumin level <.0001 ≤ 35 g/L 53 (27 %) 30 (26%) 22 (69%)> 35 g/L 123 (62 %) 74 (63%) 8 (25%)unknown 23 13 2
Hemoglobin .03 ≤ 12 g/dL 87 (44 %) 47 (40%) 21 (66%)
> 12 g/dL 99 (50 %) 59 (50%) 11 (34%)unknown 13 11
Bulky tumor (≥ 10 cm) ns absent 111 (56 %) 65 (55%) 13 (41%)present 77 (39 %) 43 (37%) 18 (56%)unknown 11 9 1
Complete remission rate .0005 yes 148 (74%) 96 (82%) 16 (50%)
no 51 (26%) 21 (18%) 16 (50%)
International Prognostic Index risk groups .003 low / intermediate low 96 (48 %) 64 (55%) 8 (25%)intermediate high / high 79 (40 %) 39 (33%) 20 (62%)unknown 24 14 4
* The associations were compared with χ2 test; ns denotes not significant
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
21
Table 2. Allele frequency and genotype distribution of the IL-10-1082, IL-10-819, IL-10-592
polymorphisms in 199 DLBCL patients and 112 healthy controls
Control DLBCL patients
n=112 n=199
Allele frequency
IL-10-1082G 0.39 0.47*
IL-10-1082A 0.61 0.53
IL-10-819C 0.68 0.745
IL-10-819T 0.32 0.255
IL-10-592C 0.68 0.745
IL-10-592A 0.32 0.255
Genotype distribution
IL-10-1082GG 20 (18%) 44 (22%) †
IL-10-1082GA 47 (42%) 100 (50%)
IL-10-1082AA 45 (40%) 55 (28%)
IL-10-819CC 53 (47%) 107 (54%)
IL-10-819CT 46 (41%) 81 (41%)
IL-10-819TT 13 (12%) 11 (5%)
IL-10-592CC 53 (47%) 107 (54%)
IL-10-592CA 46 (41%) 81 (41%)
IL-10-592AA 13 (12%) 11 (5%)
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
22
* P=.043, frequency of the IL-10-1082G allele in DLBCL patients as compared to controls; †
P=.023, frequency of the IL-10-1082GG/GA genotypes in DLBCL patients as compared to
controls. P value refers to the χ2 test
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
23
Table 3. The associations of IL-10 levels with allele frequency and genotype distribution of
the IL-10-1082, IL-10-819, IL-10-592 polymorphisms in 149 DLBCL patients who provided
samples available for ELISA at the time of initial presentation.
IL-10 (< 5 pg/mL) IL-10 (≥ 5 pg/mL)
n=117 n=32
Allele frequency
IL-10-1082G 0.45 0.53
IL-10-1082A 0.55 0.47
IL-10-819C 0.68 0.845
IL-10-819T 0.32 * 0.155
IL-10-592C 0.68 0.845
IL-10-592A 0.32 * 0.155
Genotype distribution
IL-10-1082GG 26(22%) 8(25%)
IL-10-1082GA 54 (46%) 18 (56%)
IL-10-1082AA 37 (32%) 6 (19%)
IL-10-819CC 53 (45%) 23 (72%) †
IL-10-819CT 54 (46%) 8 (25%)
IL-10-819TT 10 ( 9%) 1 (3%)
IL-10-592CC 53 (45%) 23 (72%) †
IL-10-592CA 54 (46%) 8 (25%)
IL-10-592AA 10 ( 9%) 1 (3%)
* P=.014, frequency of the IL-10-819T or IL-10-592A alleles in DLBCL patients with elevated IL-10
serum levels (≥ 5 pg/mL) versus below its detection limit (<5 pg/mL); † P=.014, frequency of the
IL-10-819CC or IL-10-592CC genotypes in DLBCL patients with elevated IL-10 serum levels (≥ 5
pg/mL) versus below its detection limit (<5 pg/mL). P value refers to the χ2 test
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
24
Legend to Figure 1. Freedom from progression (A) and overall survival (B) of 199 DLBCL
patients according to the IL-10-1082 polymorphism. The continuous lines denote the patients
carrying the IL-10-1082G allele (n=144), including IL-10-1082GG (n=44) and IL-10-1082GA (n=100)
genotypes, while the dotted lines denote the patients carrying IL-10-1082AA genotype (n=55); P
value refers to the LogRank test.
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
25
A)
(B)
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom
26
only.For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.orgFrom